AbbVie (NYSE:ABBV) Shares Down 1.3% – What’s Next?

AbbVie Inc. (NYSE:ABBV) was down 1.3% on Monday . The company traded as low as $223.98 and last traded at $224.82. Approximately 5,207,819 shares traded hands during trading, a decline of 19% from the average daily volume of 6,391,651 shares. The stock had previously closed at $227.70.

Analyst Ratings Changes

ABBV has been the topic of several research analyst reports. Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a report on Tuesday, November 4th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Finally, Wells Fargo & Company lifted their target price on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Stock Performance

The stock has a market capitalization of $397.34 billion, a PE ratio of 107.06, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm’s 50 day moving average is $227.71 and its two-hundred day moving average is $207.01.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

Institutional Investors Weigh In On AbbVie

A number of hedge funds have recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA purchased a new position in AbbVie in the second quarter worth approximately $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the 3rd quarter valued at $26,000. TD Capital Management LLC raised its holdings in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Finally, Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth $28,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.